drugset
drugset / Trial / NCT05033743

Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study

NCT05033743 ↗

Phase 2/3 Completed 24 enrolled Indiana University Lupin Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the effectiveness Secnidazole to treat recurrent BV. Secnidazole is approved for one-time use in acute BV. In this study, the drug will be used for recurrent BV, and given weekly for 18 weeks.

Timeline

Start
2021-07-09
Primary completion
2022-10-07
Completion
2022-10-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Secnidazole Small molecule 2 g Oral

Indications

bacterial vaginosis